pharmaphorum

JUNE 11, 2021

As healthcare organisations scale up digital transformation initiatives, novel problems arise: how to share data without exposing intellectual property or patient data to bad actors? In addition, advancing the training, habits and alertness of teams adds a strong layer of defence towards improving the specificity and speed of response.

Clinical Trials 109

Clinical Trials Clinical Trials Trials Compliance 109

Drug Discovery World

MAY 8, 2023

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a series of reports about the availability of new medicines throughout Europe. Delays outside company control A clear picture is also emerging about the exact points of delay.

Medicine 52

Medicine Marketing Vaccination Vaccine 52

pharmaphorum

DECEMBER 16, 2022

However, the scale of the pandemic has forced action to revise and improve upon this framework in order to react faster to future global health threats, and to ensure that such a reaction provides a more equitable response. The aim of this initiative is to speed up the response to potential threats. Vaccine access for a price.

Vaccination 91

Vaccination Vaccine Production Licensing 91

pharmaphorum

NOVEMBER 24, 2021

The initial attack locked down computers across the biomanufacturing unit, but unusually the hackers did not seem particularly aggressive about claiming a ransom payment, leading the investigation team to suspect some other purpose. Worryingly, the malware seems to be specifically designed and targeted to biomanufacturing facilities, it said.

Production 78

Production Vaccination Vaccine Engineer 78

The Pharma Data

NOVEMBER 9, 2020

About IP-001 The proprietary carbohydrate polymer IP-001 is intended to trigger a tumor-specific systemic immune response when exposed to tumor antigens liberated by ablation. About Immunophotonics, Inc. IP-001 is the first asset from the company’s intellectual property platform.

Immune Response 40

Immune Response Clinical Trials Clinical Trials Trials 40

Drug Discovery World

JULY 10, 2023

Yet when seeking to obtain an existing model, researchers often encounter obstacles related to intellectual property, availability, or licensing. Coat colour patterns are traditionally used to make an inference about the presence of the modified allele in the germline. In response, researchers often breed several founders.

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

The Pharma Data

DECEMBER 31, 2020

About Aravive Aravive, Inc. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

The Pharma Data

OCTOBER 15, 2020

The central independent evaluation showed an overall rate of response (“ORR”) of 68% and the rate of complete response (“CR”) was 59% for the 22 patients. In addition, bone marrow clearance was observed with complete response in 7 of 9 patients, who had positive bone marrow at trial start. About Y-mAbs.

Production 52

Production Development Marketing Licensing 52

Roots Analysis

APRIL 15, 2024

Further, it is worth highlighting that fill finish manufacturing is one of the most commonly outsourced operations in the biopharmaceutical industry, occupying about one-third of the total market. Drug developers prefer to outsource their fill finish manufacturing needs for several reasons.

Manufacturing 40

Manufacturing Production Contract Manufacturing Contamination 40

The Pharma Data

MAY 31, 2022

Moderna will assume responsibility for all Spikevax™ activities, including import, local regulatory, development, quality assurance and commercialization. Both companies will be responsible for ensuring proper implementation of operations associated with this transfer. “We About Moderna. About Takeda.

Vaccination 52

Vaccination Vaccine Marketing RNA 52

FDA Law Blog

SEPTEMBER 1, 2021

There are standard topics diligence typically covers: financial, employment, environmental, tax, intellectual property, and litigation, among other things. learned about the alleged conduct in Paragraphs E.1 For companies that play in the FDA-regulated space, however, a focused regulatory diligence should be a high priority.

Compliance 52

Compliance Regulation Marketing 52

The Pharma Data

NOVEMBER 27, 2020

This indication is approved under accelerated approval regulation based on overall response rate and duration of response. To learn more about Danyelza, visit DANYELZA.com. To learn more about Y-mAbs Connect, visit ymabsconnect.com. About High-Risk Neuroblastoma. About Y-mAbs.

FDA Approval 52

FDA Approval Production Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

Since announcing the Early Access Program on December 8, response from top academic institutions and leading pharmaceutical companies around the world has exceeded our expectations,” said Byron Lawson, Chief Commercial Officer. About HTG: HTG is focused on NGS-based molecular profiling.

Containment 52

Containment Production Medicine Life Science 52

FDA Law Blog

FEBRUARY 1, 2022

When FDA opened the relevant docket, the Agency asked questions about modernization of the Orange Book generally, as well as about listing of drug product patents, method-of-use patents, REMS patents, and digital application patents. However, commenters all had different perspectives about the best way to address these patents.

Production 52

Production Drugs Generic Drugs Branding 52

Pharmaceutical Technology

JULY 29, 2022

However, while there appears to be a collegiate spirit among these companies, barriers remain in partnering with other entities, with 75% of executives identifying partnering with private companies as a challenge and 86% stating the same about contract research organizations. Manufacturing agility: Index score 6.5/10.

Manufacturing 147

Manufacturing Production Contract Manufacturing Engineer 147

The Pharma Data

DECEMBER 14, 2020

“BetterLife’s acquisition of Transcend’s intellectual property allows us a rapid pathway forward to drug manufacturing and human clinical studies without the regulatory hurdles seen elsewhere in this industry,” stated Dr. Ahmad Doroudian, Chief Executive Officer of BetterLife. About BetterLife Pharma Inc. BetterLife Pharma Inc.

Drug Delivery 40

Drug Delivery Containment Manufacturing Drugs 40

The Pharma Data

DECEMBER 17, 2020

In this study, data from the RADARS ® System’s Survey of Non-Medical Use of Prescription Drugs (NMURx) Program online cross-sectional general population national surveys are analyzed from 2018 from four countries, Germany, Italy, Spain, and the UK, with 45,000 total responses. NASDAQ: FBIO). For more information, visit www.avenuetx.com.

Containment 52

Containment Production Drugs Development 52

The Pharma Data

JANUARY 11, 2021

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

DECEMBER 23, 2020

About NP-120 (Ifenprodil). About Algernon Pharmaceuticals Inc. . Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. Ifenprodil prevents glutamate signalling.

Containment 52

Containment Regulation Compliance Development 52

The Pharma Data

DECEMBER 30, 2020

“Our TAAP TM oral prodrug technology and MPAR TM overdose protection, both unique to the industry, have already demonstrated exceptional clinical results that promise to hold a prominent place in responsible prescribing of analgesics.”. About The GEM Group. Global Emerging Markets (“GEM”) is a $3.4 www.ensysce.com.

Marketing 52

Marketing Production Drugs Containment 52

The Pharma Data

JULY 27, 2021

Calico will be responsible for research and early development until 2025 and will advance collaboration projects into Phase 2a through 2030. About AbbVie AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. SOURCE AbbVie.

Life Science 52

Life Science Development Research Production 52

The Pharma Data

JUNE 25, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. About Lecanemab (BAN2401) Lecanemab is an investigational humanized monoclonal antibody for Alzheimer’s disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic.

Antibody 40

Antibody Clinical Trials Clinical Trials Development 40

The Pharma Data

NOVEMBER 17, 2021

About PF-07321332; ritonavir PF-07321332 is an investigational SARS-CoV-2 protease asset antiviral remedy, specifically designed to be administered orally so that it can be specified at the first sign of infection or at first mindfulness of an exposure, potentially helping cases avoid severe illness which can lead to hospitalization and death.

Licensing 52

Licensing Licensing Medicine Manufacturing 52

The Pharma Data

AUGUST 31, 2020

Basel, Switzerland, September 1, 2020 — Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.

Medicine 52

Medicine Containment Production Development 52

The Pharma Data

NOVEMBER 9, 2020

(NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. About Praxis. Source link.

Medicine 40

Medicine Clinical Trials Clinical Trials Containment 40

The Pharma Data

DECEMBER 5, 2020

5, 2020 /PRNewswire/ — 63% response rate in patients treated with the highest reported dose. Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 6 months of follow-up, 83% have ongoing responses for up to 13 months at the time of analysis.

Antibody 40

Antibody Production Trials Medicine 40

The Pharma Data

MAY 8, 2021

nAMD accounts for 10% of all age-related macular degeneration cases, but is responsible for 90% of AMD-related blindness 2 ,” said Florian Bieber, Global Head of Biopharmaceuticals Development, Sandoz. About aflibercept. About MYLIGHT. About Sandoz. Aflibercept is a key treatment in ophthalmology.

Clinical Development 52

Clinical Development Medicine Development Containment 52

pharmaphorum

APRIL 11, 2022

Effective intellectual property systems are also essential in stimulating research and sustainable innovation for the future. About the author. And strong collaboration from all involved in health research is another key component of a value-based healthcare approach. How can innovation within Medical Affairs drive value?

Medicine 112

Medicine Clinical Trials Clinical Trials Development 112

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer. Sokolovska, A.,

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

MAY 30, 2022

Prior to that Marie-Anne was Brand General Manager of LVMH Group’s (LVMH) Dior Perfume and Beauty business where she was responsible for strategy, brand equity, innovation, advertising, and digital. For further information please visit www.gsk.com/about-us. GSK is a science-led global healthcare company. Source link: [link].

Branding 52

Branding Life Science Business Development Marketing 52

The Pharma Data

MAY 2, 2022

Teva believes that today’s settlement with Lupin is a further reflection of the strength of its intellectual property covering its AUSTEDO product. Patent Office Patent Trial and Appeal Board declined to institute an Inter Partes Review of Teva’s compound patent for deutetrabenazine in response to a petition submitted by Apotex.

Production 52

Production Containment Medicine FDA Approval 52

The Pharma Data

JANUARY 24, 2021

Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. More information about Sairiyo is available on the company’s website which is located at www.sairiyothera.com. About PharmaDrug Inc.

Drugs 52

Drugs Containment Development Sales 52

Pfizer

FEBRUARY 16, 2023

2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. 5,6 The program was granted Fast Track designation by the U.S. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

APRIL 28, 2021

1* In both studies, significantly more patients treated with SKYRIZI achieved the primary endpoint of ACR20 response at week 24 versus placebo. 1* In both studies, significantly more patients treated with SKYRIZI achieved the primary endpoint of ACR20 response at week 24 versus placebo. About Psoriatic Arthritis.

Medicine 40

Medicine Trials Drugs Dermatology 40

The Pharma Data

FEBRUARY 22, 2021

1 A greater proportion of patients treated with upadacitinib achieved clinical response compared to placebo, with 74 percent of upadacitinib-treated patients experiencing clinical response (per Adapted Mayo Score) at week 8 versus 25 percent of patients receiving placebo (p<0.001). Clinical response (per Adapted Mayo Score) b,†.

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

JULY 29, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. About Lecanemab (BAN2401) Lecanemab is an investigational humanized monoclonal antibody for Alzheimer’s disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic.

Clinical Trials 52

Clinical Trials Clinical Trials Development Antibody 52

The Pharma Data

MAY 2, 2021

Neovascular age-related macular degeneration accounts for 10% of age-related macular degeneration cases, but is responsible for 90% of AMD-related blindness 2. About aflibercept. About MYLIGHT. About Sandoz. Aflibercept is a key treatment in ophthalmology.

Clinical Development 40

Clinical Development Medicine Development Production 40